Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Receiving Paclitaxel

Inclusion Criteria: * Women with histologically confirmed diagnosis of breast cancer (any stage) * Must be receiving either adjuvant or neo-adjuvant dose-dense anthracycline/taxane-based chemotherapy * Specifically, this study seeks to characterize neuropathies associated with patients receiving paclitaxel cycles separated by two week intervals * Patients may have received any of the following therapies: surgery, chemotherapy, hormones, biologics, or radiation * Prior chemotherapies are permitted, except with prior treatments with taxanes * Required lab values: CBC, Comprehensive Chemistry Panel * Desired lab values: If the patient's record also includes TSH, HbA1c, and folate, then those will be recorded as well * All patients will have given signed, informed consent prior to registration Exclusion Criteria: * Patients must not have received any prior taxane treatments * Patients must not have a history of peripheral neuropathy (regardless of cause) * Patient must not have a history of diabetes mellitus * Patient must not have a history of Raynaud's disease * Men are not eligible